10:19 AM EDT, 07/11/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) and Personalis ( PSNL ) agreed to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease to boost patient access to MRD testing.

The companies said Thursday they are developing ultra-sensitive MRD tests to enable earlier detection of cancer recurrence and more refined therapy monitoring compared with alternative approaches.

Myriad Genetics ( MYGN ) shares rose 2.1% in recent Thursday trading, and Personalis ( PSNL ) gained 3.4%.

Price: 25.66, Change: +0.52, Percent Change: +2.07